2025-09-28 - Analysis Report
Okay, here's an analysis of Colgate-Palmolive (CL) based on the data you've provided.  I'll present it in a structured report format with key figures and straightforward analysis.

**Colgate-Palmolive Co. (CL) Stock Analysis**

*   **Company Overview:** Colgate-Palmolive is a global consumer products company focused on the production, distribution, and provision of household, health care, and personal care products.

**1. Performance vs. S&P 500 (VOO)**

*   **Key Numbers:**
    *   CL Cumulative Return: -8.96%
    *   VOO Cumulative Return: 66.41%
    *   Cumulative Return Difference: -56.5%
    *   Relative Deviation: 5.2 (On a scale where the minimum to maximum fluctuation range is 100, the current position)
*   **Analysis:** CL has significantly underperformed the S&P 500 over the analyzed period. The large negative return difference (-56.5%) indicates substantial underperformance.  The relative deviation of 5.2 suggests the current underperformance is near the lower end of its historical range relative to the S&P 500.

* **Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
|------------|---------|---------|---------|--------|--------|
| 2015-2017  | 11.0%   | 57.2%   | 2.0%    | -0.1   | 61.0   |
| 2016-2018  | -8.0%   | 72.0%   | -6.0%   | -0.0   | 48.1   |
| 2017-2019  | 0.0%    | 72.0%   | -5.0%   | -0.1   | 55.6   |
| 2018-2020  | 1.0%    | 81.2%   | -24.0%  | -0.1   | 69.1   |
| 2019-2021  | 10.0%   | 81.2%   | -19.0%  | -0.5   | 69.0   |
| 2020-2022  | 0.0%    | 81.2%   | -14.0%  | -0.1   | 63.7   |
| 2021-2023  | 0.0%    | 80.0%   | -18.0%  | 1.0    | 64.4   |
| 2022-2024  | 14.0%   | 80.0%   | 1.0%    | 1.0    | 73.5   |
| 2023-2025  | -5.0%   | 76.6%   | -41.0%  | 0.6    | 64.3   |

*   **Analysis of the Table:**

    *   **CAGR (Compound Annual Growth Rate):** The CAGR shows varied performance over different periods. Some periods show positive growth (e.g., 2015-2017, 2019-2021, 2022-2024), while others indicate a decline (e.g., 2016-2018, 2023-2025).
    *   **MDD (Maximum Drawdown):** The MDD is consistently high across all periods, indicating substantial risk or volatility in the stock's price movements.
    *   **Alpha:** The Alpha values are mostly negative, implying that the stock has generally underperformed its benchmark index (S&P 500) during these periods.
    *   **Beta:** The Beta values vary, indicating different levels of volatility relative to the market. A Beta of 1.0 (as seen in 2021-2023 and 2022-2024) suggests the stock's price moves in tandem with the market.
    *   **Cap(B) (Market Capitalization in Billions):** The market capitalization has fluctuated, reflecting changes in the company's valuation.

**2. Recent Stock Price Movements**

*   **Key Numbers:**
    *   Current Price: 79.59
    *   Previous Close: 79.70
    *   Change: -0.14
    *   5-day Moving Average: 80.186
    *   20-day Moving Average: 82.4285
    *   60-day Moving Average: 85.245
*   **Analysis:** The current price is slightly down from the previous close.  The stock price is below all three moving averages (5-day, 20-day, and 60-day), which typically indicates a short-term downtrend.  The gap between the 5-day and 60-day moving averages suggests a sustained downward trend over the past couple of months.

**3. Market Risk Indicators and Expected Return**

*   **Key Numbers:**
    *   Market Risk Indicator (MRI): 0.9 (High Investment Recommended)
    *   RSI: 30.10
    *   PPO: -0.27
    *   Hybrid Signal: cash_0%_Buy 100% of cash (11 shares - Very Safe - MRI:0.90)
    *   Recent (20-day) Relative Deviation Change: 5.2 (+) - Short-term increase
    *   Expected Return: -481.9%
*   **Analysis:**
    *   The high MRI score (0.9) suggests the market, in general, is considered a relatively safe investment environment.
    *   The RSI of 30.10 indicates that the stock may be approaching oversold territory, potentially signaling a buying opportunity for some investors.
    *   The PPO of -0.27 suggests that the short-term moving average is below the long-term moving average, which is typically bearish.
    *   The positive change in relative deviation (+5.2) over the past 20 days suggests some recent improvement in CL's performance relative to VOO, but this is a short-term trend.
    *   The extremely negative expected return (-481.9%) is a significant red flag.  It suggests that based on the model's calculations, long-term investment in CL is projected to dramatically underperform the S&P 500.
    *   The slight price drop (-0.14) from the previous close doesn't represent a major volatility event.

**4. Recent News & Significant Events**

*   **Summary of Headlines:**
    *   Some articles highlight CL as a stock to consider within the S&P 500.
    *   Others focus on Colgate's strategic initiatives and innovation.
    *   Analyst opinions are mixed, with some firms adjusting price targets downward.
    *   Dividend strategy articles mention CL's role as a dividend stock.
*   **Analysis:** The news headlines present a mixed picture. While some articles highlight potential growth drivers, the downward price target adjustments from Wells Fargo and RBC suggest some concerns about the company's near-term performance. The focus on dividends indicates that CL is potentially viewed as a stable, income-generating investment, which might attract investors seeking lower-risk options.

**4-2. Analyst Opinions**

*   **Key Numbers:**
    *   Consensus: Buy (~2.05)
    *   Target Price: 95.22 (Avg) / 106.00 (High) / 83.00 (Low)
*   **Analysis:** The analyst consensus is leaning towards a "Buy" rating with an average price target of $95.22. This suggests that analysts, on average, believe the stock is currently undervalued and has upside potential. However, the range of target prices is wide, indicating some uncertainty in their forecasts.

**5. & 6. Recent Earnings and Financial Information Analysis**

* **Earnings Data:**

| 날짜       | EPS    | 매출        |
|------------|--------|-------------|
| 2025-08-01 | 0.92   | 5.11 B$     |
| 2025-04-25 | 0.85   | 4.91 B$     |
| 2024-10-25 | 0.90   | 5.03 B$     |
| 2024-07-26 | 0.89   | 5.06 B$     |
| 2025-08-01 | 0.89   | 5.06 B$     |

* **Analysis of Earnings:**

    *   **EPS (Earnings Per Share):** The EPS has shown some variability but has generally remained around $0.85 to $0.92.
    *   **Revenue:** The revenue has fluctuated between $4.91B and $5.11B.
    *   **Note:** There's a duplicate entry for 2025-08-01, which might indicate a data entry error.

* **Financial Information:**

Revenue and Profitability:

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30   | $5.11B    | 60.06%        |
| 2025-03-31   | $4.91B    | 60.82%        |
| 2024-12-31   | $4.95B    | 60.30%        |
| 2024-09-30   | $5.03B    | 61.08%        |
| 2024-06-30   | $5.06B    | 60.62%        |

Capital and Profitability:

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2025-06-30   | $0.70B    | 105.84%   |
| 2025-03-31   | $0.36B    | 190.08%   |
| 2024-12-31   | $0.21B    | 348.58%   |
| 2024-09-30   | $0.43B    | 169.43%   |
| 2024-06-30   | $0.12B    | 594.31%   |

* **Analysis of Financial Data:**

    *   **Revenue:** The revenue has been relatively stable, ranging from $4.91B to $5.11B per quarter.
    *   **Profit Margin:** The profit margin has consistently remained high, around 60-61%, indicating strong operational efficiency.
    *   **Equity:** The equity has fluctuated, and the values seem quite low compared to the revenue and market cap, which may require further investigation.
    *   **ROE (Return on Equity):** The ROE values are exceptionally high, suggesting the company is generating significant profits relative to its equity. However, the low equity values raise questions about the sustainability of these high ROE figures.

**7. Overall Analysis and Summary**

Colgate-Palmolive (CL) presents a mixed investment picture:

*   **Negative Aspects:**
    *   Significant underperformance relative to the S&P 500 (VOO).
    *   Negative expected return, suggesting potential for continued underperformance.
    *   The stock price is trading below its key moving averages, indicating a downtrend.
    *   High MDD indicating substantial risk or volatility in the stock's price movements.
*   **Positive Aspects:**
    *   Analysts have a generally positive outlook ("Buy" consensus).
    *   High MRI score, suggesting a generally safe market environment.
    *   The company maintains strong and consistent profit margins.
*   **Mixed Signals:**
    *   Recent news headlines are a mixed bag of positive and negative sentiment.
    *   Low equity values and exceptionally high ROE figures warrant further scrutiny.
*   **Investment Recommendation:**
    Given the underperformance, negative expected return, and mixed analyst opinions, a cautious approach is warranted. While the analyst consensus suggests upside potential, the risks highlighted by the performance metrics and news headlines should be carefully considered. Further research into the company's financial statements and strategic plans is recommended before making an investment decision.
